Maintenance therapy with K-CAB 25 mg for GERD patients after initial treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In a routine clinical setting, adults with GERD who have completed initial treatment will continue taking K-CAB 25 mg tablets or ODT as maintenance therapy. The study will observe heartburn and acid regurgitation over time and collect safety information, including potential risks. No formal comparison or randomization is described; the focus is on real-world use and safety in ongoing care. Data will come from participants as prescribed by their physicians, reflecting everyday practice.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Aged 19 years or older on the date written informed consent is obtained
2. Determined by the investigator, based on medical judgment, to receive K-CAB Tab/K-CAB ODT 25 mg
3. Scheduled to receive K-CAB Tab/K-CAB ODT 25 mg, as maintenance therapy following treatment for gastroesophageal reflux disease (GERD)
4. Voluntarily agrees to participate in the study and provides written informed consent

Exclusion Criteria:

1. Individuals who meet any of the contraindications listed under "Contraindications" in the "Precautions for Use" section of the approved prescribing information for K-CAB Tab/K-CAB ODT 25 mg
2. Individuals whom the investigator considers unsuitable for participation in this study for any other reason

Where it's running

• HK inno.N
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Yong-an Jeong
• Email: yongan.jeong@inno-n.com
• Phone: +82-31-5176-4673

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational look at how Kremezin works in adults with advanced chronic kidney disease

  This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07930169

• Observational study of achieving LDL targets with Rovazet tablets in dyslipidemia

  This study follows patients with dyslipidemia who are prescribed Rovazet to see how well reaching LDL targets works in routine care over 48 weeks.

  Recruiting HK inno.N Corporation · Seoul · NCT07924345

• Gerd symptoms with tegoprazan treatment in adults

  This study tests whether tegoprazan 50 mg (tablet or dispersible tablet) helps GERD symptoms and is safe in adults who meet criteria.

  Recruiting HK inno.N Corporation · Seoul · NCT07678177

• Topical IN-115314 Ointment in mild to moderate atopic dermatitis

  This study tests whether IN-115314 ointment (1% or 3%) works and is safe in adults with mild to moderate atopic dermatitis compared with a placebo.

  Recruiting Phase 2 HK inno.N Corporation · Ansan, ALL · NCT07073677

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.